Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin Sodium Salt
2. Bridion
3. Org 25969
4. Sugammadex
1. 343306-79-6
2. Bridion
3. Org 25969
4. Org-25969
5. Erj6x2mxv7
6. 343306-71-8
7. Sugammadex Octasodium Salt
8. Sugammadex (sodium)
9. Unii-erj6x2mxv7
10. Sugammadex Sodium [usan]
11. Sugammadexsodium
12. Sugammadex Sodium [usan:jan]
13. Bridion (tn)
14. Mk-8616
15. Org25969
16. Sugammadex Sodium (jan/usan)
17. Sugammadex Sodium [jan]
18. Chebi:90952
19. Sugammadex Sodium [mart.]
20. Sugammadex Sodium [who-dd]
21. Amy12422
22. Ex-a2600
23. Sch-900616
24. Sugammadex Octasodium Salt [mi]
25. Sugammadex Sodium [orange Book]
26. Ac-30384
27. C13789
28. D05940
29. .gamma.-cyclodextrin, 6a,6b,6c,6d,6e,7f,6g,6h-octakis-s-(2-carboxyethyl)-6a,6b,6c,6d,6e,7f,6g,6h-octathio-, Octasodium Salt
30. Gamma-cyclodextrin, 6a,6b,6c,6d,6e,7f,6g,6h-octakis-s-(2-carboxyethyl)-6a,6b,6c,6d,6e,7f,6g,6h-octathio-, Octasodium Salt
31. Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-s-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-d-octaglucopyranoside
| Molecular Weight | 2178.0 g/mol |
|---|---|
| Molecular Formula | C72H104Na8O48S8 |
| Hydrogen Bond Donor Count | 16 |
| Hydrogen Bond Acceptor Count | 56 |
| Rotatable Bond Count | 32 |
| Exact Mass | 2176.2644287 g/mol |
| Monoisotopic Mass | 2176.2644287 g/mol |
| Topological Polar Surface Area | 995 Ų |
| Heavy Atom Count | 136 |
| Formal Charge | 0 |
| Complexity | 2790 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 40 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 9 |
Reversal of neuromuscular blockade induced by rocuronium or vecuronium.
For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
V03AB35
V03AB35
V03AB35
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;INTRAVENOUS - EQ 200MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 200MG BASE/2ML (EQ 100MG BASE/ML)
USFDA APPLICATION NUMBER - 22225
DOSAGE - SOLUTION;INTRAVENOUS - EQ 500MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 500MG BASE/5ML (EQ 100MG BASE/ML)
USFDA APPLICATION NUMBER - 22225
Related Excipient Companies
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
64
PharmaCompass offers a list of Sugammadex Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sugammadex Sodium manufacturer or Sugammadex Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sugammadex Sodium manufacturer or Sugammadex Sodium supplier.
PharmaCompass also assists you with knowing the Sugammadex Sodium API Price utilized in the formulation of products. Sugammadex Sodium API Price is not always fixed or binding as the Sugammadex Sodium Price is obtained through a variety of data sources. The Sugammadex Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 343306-71-8 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 343306-71-8, including repackagers and relabelers. The FDA regulates 343306-71-8 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 343306-71-8 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 343306-71-8 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 343306-71-8 supplier is an individual or a company that provides 343306-71-8 active pharmaceutical ingredient (API) or 343306-71-8 finished formulations upon request. The 343306-71-8 suppliers may include 343306-71-8 API manufacturers, exporters, distributors and traders.
click here to find a list of 343306-71-8 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 343306-71-8 DMF (Drug Master File) is a document detailing the whole manufacturing process of 343306-71-8 active pharmaceutical ingredient (API) in detail. Different forms of 343306-71-8 DMFs exist exist since differing nations have different regulations, such as 343306-71-8 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 343306-71-8 DMF submitted to regulatory agencies in the US is known as a USDMF. 343306-71-8 USDMF includes data on 343306-71-8's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 343306-71-8 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 343306-71-8 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 343306-71-8 Drug Master File in Japan (343306-71-8 JDMF) empowers 343306-71-8 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 343306-71-8 JDMF during the approval evaluation for pharmaceutical products. At the time of 343306-71-8 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 343306-71-8 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 343306-71-8 Drug Master File in Korea (343306-71-8 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 343306-71-8. The MFDS reviews the 343306-71-8 KDMF as part of the drug registration process and uses the information provided in the 343306-71-8 KDMF to evaluate the safety and efficacy of the drug.
After submitting a 343306-71-8 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 343306-71-8 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 343306-71-8 suppliers with KDMF on PharmaCompass.
A 343306-71-8 written confirmation (343306-71-8 WC) is an official document issued by a regulatory agency to a 343306-71-8 manufacturer, verifying that the manufacturing facility of a 343306-71-8 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 343306-71-8 APIs or 343306-71-8 finished pharmaceutical products to another nation, regulatory agencies frequently require a 343306-71-8 WC (written confirmation) as part of the regulatory process.
click here to find a list of 343306-71-8 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 343306-71-8 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 343306-71-8 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 343306-71-8 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 343306-71-8 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 343306-71-8 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 343306-71-8 suppliers with NDC on PharmaCompass.
343306-71-8 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 343306-71-8 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 343306-71-8 GMP manufacturer or 343306-71-8 GMP API supplier for your needs.
A 343306-71-8 CoA (Certificate of Analysis) is a formal document that attests to 343306-71-8's compliance with 343306-71-8 specifications and serves as a tool for batch-level quality control.
343306-71-8 CoA mostly includes findings from lab analyses of a specific batch. For each 343306-71-8 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
343306-71-8 may be tested according to a variety of international standards, such as European Pharmacopoeia (343306-71-8 EP), 343306-71-8 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (343306-71-8 USP).
